RXi Pharmaceuticals Awarded NCI SBIR Funding
News Oct 12, 2012
RXi Pharmaceuticals Corporation has announced that it was awarded a Small Business Innovation Research (SBIR) grant by the National Cancer Institute (NCI) of the National Institutes of Health (NIH).
The grant provides funding for a project enabling the discovery and preclinical development of sd-rxRNAs® as potential therapy for retinoblastoma, a pediatric ocular malignancy.
The project will be completed in collaboration with Dr. David Cobrinik and colleagues at the Memorial Sloan-Kettering Cancer Center.
Dr. Cobrinik commented, "Prior studies performed by RXi and their collaborators at the University of Massachusetts, demonstrated that self-delivering sd-rxRNAs can penetrate the retina and regulate retinal gene expression. As retinoblastomas form within the retina, we hypothesized that sd-rxRNAs might also regulate gene expression in intraocular retinoblastoma cells. This SBIR award will enable us to test this hypothesis, possibly extending the application of sd-rxRNAs from ophthalmic diseases to the cancer setting."
RXi has been awarded approximately $300,000 to fund the collaborative project over six months.
Under this grant (R43CA165899), entitled "Development of sd-rxRNAs® as Therapy for Retinoblastoma and Other Malignancies", sd-rxRNA compounds will be developed to silence one or more targets critical to retinoblastoma cell growth and survival.
The sd-rxRNA compounds will be evaluated for efficacy in in vivo models of retinoblastoma by the Cobrinik lab.
"We are honored to have the opportunity to collaborate with the team at Memorial Sloan-Kettering, and are very pleased to have received financial support from the NCI to further the development of our novel RNAi compounds as potential therapeutics for ocular cancer," said Pamela Pavco, Chief Development Officer at RXi Pharmaceuticals.
Pavco continued, "The grant process is highly competitive, and this award serves to recognize and support the therapeutic potential of RXI's proprietary RNAi platform."
The Small Business Innovation Research (SBIR) program was created by the U.S. Congress to strengthen the role of small, innovative companies in federally supported research and development.
It is one of the largest sources of early-stage technology financing in the U.S. At the National Cancer Institute (NCI), these programs seek small business participation in the development and commercialization of technologies for the treatment and diagnosis of cancer.
Sphere Fluidics and Geneva Biotech Receive Eurostars Genome Editing GrantNews
€1.6 million grant will support ‘precise docking of very large DNA cargoes in genomes’ project.READ MORE
RNAi-based Drug Shows Promise as Treatment for Chronic Hepatitis BNews
The novel therapy by Arrowhead Pharmaceuticals uses a mechanism called RNA interference to reduce the surface antigens created by chronic HBV infections.READ MORE
A More Effective Alternative to RNAi, CRISPR for Studying Protein FunctionNews
Trim-Away is a novel method enabling researchers to directly and rapidly destroy any protein in any kind of cell.READ MORE